Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.78 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.78 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.78 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.78 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.78 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.78 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.78 |
| ▸ | PRKDC | P78527 | 1/20 | 0.78 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.78 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309201 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL1309198 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL20692869 | 0.95 | PIK3CA (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL29880111 | 0.95 | PIK3CA (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL18117884 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL18117890 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL1309910 | 0.89 | MTOR (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL1310010 | 0.89 | MTOR (1.00) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL1310025 | 0.89 | MTOR (0.80) | MTORPIK3CAPIK3R1RPTORMLST8 | |
| SCHEMBL1309306 | 0.89 | MTOR (0.80) | MTORPIK3CAPIK3R1RPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | claimed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | claimed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | claimed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-11414426-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2022-08-16 | — | — | US | claimed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | claimed |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| WO-2025125469-A1 | COMBINATION THERAPY USING PSMA-TARGETED RADIOPHARMACEUTICALS AND AN INHIBITOR OF PI3K, AKT, AND/OR MTOR | SWISS ROCKETS AG (CH) | 2025-06-19 | — | — | WO | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885PIK3R1 21/4885 |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | MTOR 4135/4885PIK3CA 3499/4885PIK3R1 2951/4885 |
| US-20260062419-A1 | TREATMENT OF SKIN DISORDERS | POLR1C, CCR1, COL1A1 | MTOR 3397/4885PIK3CA 3453/4885PIK3R1 3285/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885PIK3R1 2100/4885 |
| US-20230014057-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CCR3, CBR3 | MTOR 3212/4885PIK3CA 4158/4885PIK3R1 2100/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | MTOR 4135/4885PIK3CA 3499/4885PIK3R1 2951/4885 |
| US-11414426-B2 | Treatment of skin disorders | RXFP3, CBR3, CXCR3 | MTOR 2897/4885PIK3CA 3974/4885PIK3R1 1902/4885 |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885PIK3R1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.